Introduction
============

Hypertension represents one of the most common conditions associated with increased cardiovascular risk, including stroke, myocardial infarction and heart failure.^[@bib1]^ Numerous experimental and clinical research data have shown that hypertension is associated with significant endothelial dysfunction, which may represent a major pathogenic link between hypertension and coronary artery disease.^[@bib2],\ [@bib3]^

Coronary artery spasm (CAS) plays an important role in the pathogenesis of vasospatic angina and acute coronary syndrome. Some earlier studies have suggested that patients with CAS have a disturbance in the endothelial function of the coronary arteries.^[@bib4],\ [@bib5],\ [@bib6]^ Thus, it is reasonable to speculate that patients with hypertension may have a higher incidence of significant CAS. However, only several studies designed to analyse the multiple risk factors for CAS have briefly evaluated the impact of hypertension on CAS, and no earlier study to date has analysed the impact of the status of blood pressure control on CAS.^[@bib7],\ [@bib8],\ [@bib9]^ Therefore, in this study, we evaluated the impact of hypertension and the status of blood pressure control on CAS with intracoronary acetylcholine (ACh) provocation test in a series of Korean hypertensive patients.

Materials and methods
=====================

Study population
----------------

The study flow chart was shown in [Figure 1](#fig1){ref-type="fig"}. A total of 986 patients, 685 patients with hypertension and 301 patients with normotension were enrolled into this study. The study protocol was approved by the institutional review board at Korea University, Guro Hospital (Seoul, Korea) and written informed consent was obtained from every patient before study entry.

Acetylcholine provocation test
------------------------------

Coronary artery spasm was induced by intracoronary injection of ACh after diagnostic catheterization in the morning. The details of the method were reported earlier.^[@bib10],\ [@bib11]^ In brief, nitrates, calcium channel blockers (CCBs), β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and other vasodilators or vasoconstrictors were withheld at least 72 h before coronary angiography. ACh was injected in incremental doses of 20 (A1), 50 (A2) and 100 (A3) μg into the left coronary artery over a 1 min period with 5 min intervals to the maximum tolerated dose under continuous monitoring of electrocardiogram (ECG) and blood pressure. Angiography was repeated after each ACh dose. After that, an intracoronary infusion with 0.2 mg nitroglycerin was given. Angiography was then performed 2 min later. If focal or diffuse significant vasoconstriction of coronary arteries was induced with any dose of ACh, the ACh infusion was stopped. End-systolic and end-diastolic images for each segment of the left coronary artery were chosen according to the corresponding points on the electrocardiographic trace (QRS onset or end of T wave) and analysed using the proper quantitative coronary angiographic system of the catheterization laboratory (BH-3000, Philips, Amsterdam, The Netherlands). The quantitative measuring variable was described as percent change from baseline on an angiogram. Two expert observers analysed the angiographic images at right anterior oblique cranial views and the evaluated QCA data were entered into the database. The percent diameter change was measured at the most severely narrowed site of the significantly spastic artery.

Study definitions
-----------------

Brachial blood pressure was measured in triplicate in the right arm with a cuff and mercury sphygmomanometer after the patient rested in a seated position for 5 min. The average of the last two measurements was used as brachial blood pressure. Pulse pressure was calculated as the difference between systolic and diastolic pressures. Hypertension was diagnosed according to the following criteria: (1) a history of diagnosed hypertension status and treatment with medications, diet and/or exercises; (2) systolic blood pressure ⩾140 mm Hg or diastolic blood pressure ⩾90 mm Hg on at least two occasions; (3) current use of antihypertensive pharmacological therapy to control hypertension.^[@bib12]^ In this retrospective study, we reviewed all the hypertensive patients\' in-hospital medical records about blood pressure before the temporal cessation of vasodilators; if the hypertensive patient\'s systolic blood pressure was ⩾140 mm Hg or diastolic blood pressure was ⩾90 mm Hg with the treatment of antihypertensive agents on calm occasions, he or she was identified as an uncontrolled blood pressure patient or else as a controlled blood pressure patient.

Hyperlipidaemia was defined as total cholesterol level ⩾200 mg per 100 ml or current treatment with lipid-lowering drugs. Current cigarette smoking was defined as active smoking within the past 12 months. Diabetes was defined as fasting blood glucose ⩾126 mg per 100 ml, or the use of hypoglycaemic agents or insulin. Peripheral arterial disease (PAD) was defined as a claudication symptom with ankle brachial indexes \<0.90, and/or a claudication symptom with any angiographic finding of significant lesion in the peripheral artery and/or symptomatic carotid or subclavian arterial disease documented by image studies.

During the ACh provocation test, significant CAS was defined as a \>70% decrease in the arterial luminal diameter with concurrent chest pain and/or ST-segment elevation or depression ⩾1 mm. Myocardial bridge was considered when the characteristic phasic compression of the coronary artery had a \>30% decrease in diameter on the angiogram after intracoronary nitroglycerin infusion.^[@bib10],\ [@bib11]^

Statistical analysis
--------------------

All the statistical analyses were performed using SPSS 11.0 (SPSS Inc., Chicago, IL, USA). For continuous variables, differences between groups were evaluated by unpaired *t*-test or Mann--Whitney rank-sum test. For discrete variables, differences were expressed as counts and percentages and analysed with χ^2^ (or Fisher\'s exact) test between groups as appropriate. Multivariate logistic regression analysis, which included baseline confounding factors, was used for assessing the independent impact of hypertension or the status of blood pressure control on ACh-induced significant CAS. A two-tailed *P*-value of \<0.05 was considered to be statistically significant. Data were expressed as mean±standard deviation (s.d.).

Results
=======

Impact of hypertension on coronary artery spasm
-----------------------------------------------

The baseline clinical characteristics of normotensive and hypertensive patients are presented in [Table 1](#tbl1){ref-type="table"}. Patients with hypertension were older, had higher body mass index, systolic and diastolic blood pressure, pulse pressure and more frequently had diabetes, hyperlipidaemia and PAD, but less frequently had current smoking compared with those with normotension. Accordingly, hypertensive patients had higher rates of use aspirin, β-blockers, CCBs, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and statins than did normotensive patients. Even though there was a trend towards a higher level of blood triglyceride in hypertensive patients, the blood levels of total cholesterol, low- and high-density lipoprotein cholesterol were similar between these two groups, reflecting the higher rate of use statins in hypertensive patients.

The characteristics of ACh provocation test were presented in [Table 2](#tbl2){ref-type="table"}. The reference diameters (mm) (1.84±0.49 vs 1.81±0.47, *P*=0.504) and diameter narrowing (%) (37.64±34.42 vs 39.39±32.75, *P*=0.729) of the coronary artery after ACh infusion were similar between patients with and without hypertension. Furthermore, the reference diameters of the coronary artery after nitroglycerin infusion were also similar between these two groups (mm) (2.58±0.54 vs 2.66±0.59, *P*=0.119). On account of the above results, the incidences of ACh-induced significant CAS did not differ significantly between patients with and without hypertension (35.8 vs 39.2%, *P*=0.303). During ACh provocation test, the incidences of ST-segment change, chest pain, atrioventricular block and myocardial bridge were similar between these two groups.

In patients who had significant CAS, the characteristics of CAS were also similar between patients with and without hypertension, including the maximal tolerable doses of ACh, spasm types (focal vs diffuse) and spasm vessel number ([Table 3](#tbl3){ref-type="table"}).

As shown in [Figure 2](#fig2){ref-type="fig"}, the univariate logistic analysis in the general study population showed that ageing, male, hyperlipidaemia, current smoking, PAD and myocardial bridge were risk factors for ACh-induced significant CAS. However, multivariate logistic analysis showed that besides ageing, male, PAD and myocardial bridge, hypertension was an independent predictor, too. Hypertension was negatively associated with ACh-induced CAS in multivariate logistic analysis (odds ratio: 0.70, 95% confidence interval: 0.51--0.94, *P*=0.020).

Impact of the status of blood pressure control on coronary artery spasm in hypertensive patients
------------------------------------------------------------------------------------------------

The baseline clinical characteristics of hypertensive patients with and without controlled blood pressure were similar, except that hypertensive patients with controlled blood pressure more frequently had hyperlipidaemia and PAD, and had higher rates of use nitrates and CCBs but a lower rate of use angiotensin II receptor blockers than those with uncontrolled blood pressure ([Table 4](#tbl4){ref-type="table"}).

The characteristics of ACh provocation test showed that although the diameter narrowing after ACh infusion were similar between these two groups, hypertensive patients with controlled blood pressure had a significantly higher incidence of significant CAS (45.2 vs 27.9%, *P*\<0.001). More patients in the controlled blood pressure group had myocardial bridge and chest pain during the provocation test than did those in the uncontrolled blood pressure group ([Table 5](#tbl5){ref-type="table"}).

In the hypertensive patients who had significant CAS, the characteristics of CAS were also similar between patients with and without controlled blood pressure, including spasm types (focal vs diffuse) and spasm vessel number. However, there was a trend towards a higher rate of significant CAS at A2 dose in hypertensive patients with controlled blood pressure than in those without controlled blood pressure (61.7 vs 51.0%, *P*=0.093) ([Table 6](#tbl6){ref-type="table"}).

The multivariate logistic analysis, including the aforementioned parameters, showed that uncontrolled blood pressure was negatively associated with ACh-induced significant CAS (odds ratio: 0.56, 95% confidence interval: 0.40--0.79, *P*=0.001) ([Figure 3](#fig3){ref-type="fig"}).

Discussion
==========

Numerous experimental and clinical research data have shown that hypertension is associated with significant endothelial dysfunction.^[@bib2]^ Therefore, the association between hypertension and endothelial dysfunction has been well established. Some studies have suggested that CAS is also associated with endothelial dysfunction.^[@bib4],\ [@bib5],\ [@bib6],\ [@bib13]^ Kugiyama *et al.*^[@bib5]^ reported that there was a deficiency in endothelial nitric oxide activity in spasm arteries, which was responsible for the supersensitive reaction of the coronary artery resulting in the vasoconstrictor effect of ACh in patients with CAS. Similarly, another study from Kugiyama *et al.*^[@bib6]^ indicated that flow-dependent coronary dilation is impaired in spasm arteries, partly because of a deficiency in endothelial nitric oxide bioactivity. Recently, Yasue *et al.*^[@bib13]^ tested whether fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin), could suppress coronary spasm based on the hypothesis that coronary spasm is associated with endothelial dysfunction. Their results showed that the addition of fluvastatin 30 mg per day to the conventional CCB therapy for 6 months significantly reduced the number of patients with ACh-induced coronary spasm as compared with the conventional CCB therapy. Thus, in view of the above studies,^[@bib4],\ [@bib5],\ [@bib6],\ [@bib13]^ it seems reasonable to conclude that CAS is associated with coronary endothelial dysfunction.

In this context, we tested the hypothesis that hypertensive patients might have a higher incidence of CAS than normotensive ones. In addition, some earlier studies^[@bib14],\ [@bib15]^ have shown that medical treatment with controlled blood pressure can significantly reduce the incidence of cardiovascular events in hypertensive patients. However, the impact of the status of blood pressure control on the incidence of CAS has not been reported yet. Therefore, we also performed a subgroup analysis in hypertensive patients to test the hypothesis that the controlled blood pressure might be associated with a lower incidence of CAS because of the potentially improved endothelial function with medical treatment. However, in contrast to our initial expectation, hypertension and uncontrolled blood pressure were actually seen to be negatively associated with CAS as assessed by the intracoronary ACh provocation test. In this study, although hypertensive and normotensive patients had similar incidences of ACh-induced significant CAS and diameter narrowing after ACh infusion, multivariate logistic analysis showed that hypertension was negatively associated with ACh-induced significant CAS. The subgroup analysis performed in hypertensive patients showed that hypertensive patients with controlled blood pressure had a significantly higher incidence of CAS than those without, and that uncontrolled blood pressure was negatively associated with ACh-induced significant CAS. Therefore, collectively, our results suggested that lower blood pressure rather than higher blood pressure was positively associated with CAS. Patients with hypertension had a lower incidence of CAS compared with those with normotension, and this result seems to be driven mainly by the lower incidence of CAS in hypertensive patients with uncontrolled blood pressure.

The paradoxical impact of hypertension and the status of blood pressure control on CAS might be explained as follows. First, ACh has dual effects on the coronary artery tone depending on their intracoronary concentration. The normal response to ACh is vasodilation at small doses and vasoconstriction at higher doses when the direct vasoconstrictor effect of ACh overwhelms the stimulation of nitric oxide release. Thus, ACh-induced CAS in this study, we feel, does not necessarily signify endothelial dysfunction.^[@bib16],\ [@bib17],\ [@bib18]^ Furthermore, the lack of vasodilation at small doses or mild degrees of vasoconstriction, which was not recognized as significant CAS, also reflects endothelial dysfunction.^[@bib19],\ [@bib20]^ Thus, our results do not contradict the well-established concept that hypertension is closely associated with endothelial dysfunction.

Second, earlier studies have suggested that the pathogenesis of coronary vasospasm unassociated with significant coronary atherosclerosis differed from that of atherosclerosis because the major atherosclerotic risk factors, such as hyperlipidaemia and diabetes mellitus, were not significantly associated with CAS.^[@bib8],\ [@bib21],\ [@bib22]^ Our results also supported this and showed that hyperlipidaemia and diabetes were not associated with CAS. Furthermore, beyond our initial expectation, we surprisingly found that hypertension and uncontrolled blood pressure were negatively associated with CAS. Therefore, more studies are needed to explore the mechanisms behind the association between hypertension and CAS.

Although the conventional risk factors for atherosclerosis such as hypertension, diabetes mellitus, hyperlipidaemia and smoking have been well established during the past several decades, less has been known about the risk factors for CAS. Several studies have analysed the risk factors for CAS, but the results seem varied.^[@bib8],\ [@bib21],\ [@bib22]^ Xiang *et al.*^[@bib8]^ reported the risk factors for ACh-induced CAS and showed that there was no significant association between CAS and sex, age, hypertension and positive treadmill test, but that smoking and hyperlipidaemia were independent risk factors for ACh-induced significant CAS. Kido *et al.*^[@bib21]^ reported that smoking and family history in females were the most important risk factors for CAS, whereas other cardiovascular risk factors such as hypertension, hyperlipidaemia and diabetes did not show significant correlations with ACh-induced significant CAS. Sugiishi *et al.*^[@bib22]^ also showed that smoking was the major risk factor for CAS, but the lipid levels and diabetes mellitus were not independent risk factors for it.

Our present study showed that ageing, male, peripheral artery disease and myocardial bridge were independent risk factors for ACh-induced significant CAS. Our earlier study showed that myocardial bridge was significantly associated with CAS and was independent from the other cardiovascular risk factors.^[@bib10],\ [@bib11]^ Thus, in this study, we co-analysed myocardial bridge with other cardiovascular risk factors. Interestingly, our results showed that hypertension and uncontrolled blood pressure were negatively associated with ACh-induced significant CAS. These results are consistent with the results from Sugiishi *et al.*^[@bib22]^ They also found that hypertension was negatively associated with CAS in a multivariate logistic analysis. However, in their study, they did not analyse the impact of the status of blood pressure control on the incidence of CAS.

Study limitations
-----------------

This study has several obvious limitations. First, even though we minimized the confounding effects from the baseline biases with the multivariate logistic analysis, it is possible that some potential confounders might have crept in. However, we tested CAS in a relatively large study population, which is helpful in minimizing the confounding effects from the baseline biases. Second, angiographic evaluation of the changes in epicardial coronary diameter after the infusion of ACh as used in this study mainly reflects the functional status of coronary conduit vessels but not that for coronary microcirculation because hypertension affects not only the coronary conduit artery but also microcirculations.^[@bib23],\ [@bib24]^ Thus, further studies measuring not only the coronary conduit artery spasm but also the coronary microvascular spasm in hypertensive patients are needed. Third, although we had carefully made the diagnosis of hypertension and thoroughly collected the information in detail about blood pressure for every patient, we did not collect the patient\'s blood pressure during the provocation test. However, some patients\' blood pressure level might have obviously changed after they stopped their antihypertensive treatment. Fortunately, no patient in this study was found to have cardiovascular complications because of the provocation test and the temporal medication cessation.
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###### Baseline clinical characteristics of the general study population

  *Variables*                                             *NTN (*n=*301)*   *HTN (*n=*685)*  P*-value*
  ------------------------------------------------------ ----------------- ----------------- -----------
  Male, *n* (%)                                             155 (51.5)        327 (47.7)     0.277
  Age (years)                                               50.45±12.20       55.71±11.93    \<0.001
  Body mass index (kg m^−2^)                                23.38±3.53        24.25±3.14     0.002
  Diabetes mellitus, *n* (%)                                 20 (6.6)          86 (12.6)     0.006
  Hyperlipidemia, *n* (%)                                     9 (3.0)         119 (17.4)     \<0.001
  Current smoking, *n* (%)                                   87 (28.9)        144 (21.0)     0.007
  Family history of coronary artery disease, *n* (%)         20 (6.6)          42 (6.1)      0.760
  Peripheral arterial disease, *n* (%)                        3 (1.0)          78 (11.4)     \<0.001
  Systolic blood pressure (mm Hg)                          119.91±11.02      145.68±21.04    \<0.001
  Diastolic blood pressure (mm Hg)                          73.41±7.23        87.47±11.65    \<0.001
  Pulse pressure (mm Hg)                                    46.50±8.78        58.20±15.71    \<0.001
  Total cholesterol (mg per 100 ml)                        172.04±38.30      176.51±39.15    0.109
  Triglyceride (mg per 100 ml)                             121.86±79.37      134.67±96.14    0.064
  Low-density lipoprotein cholesterol (mg per 100 ml)      111.84±35.82      114.76±57.03    0.565
  High-density lipoprotein cholesterol (mg per 100 ml)      51.50±14.00       52.40±17.96    0.482
  Aspirin, *n* (%)                                           41 (13.6)        180 (26.3)     \<0.001
  Cilostazol, *n* (%)                                         8 (2.7)          13 (1.9)      0.447
  β-Blockers, *n* (%)                                        14 (4.7)          62 (9.1)      0.017
  Calcium channel blockers, *n* (%)                         115 (38.2)        323 (47.2)     0.009
  Angiotensin-converting enzyme inhibitors, *n* (%)           5 (1.7)          32 (4.7)      0.022
  Angiotensin II receptor blockers, *n* (%)                  11 (3.7)          94 (13.7)     \<0.001
  Nitrates, *n* (%)                                          90 (29.9)        174 (25.4)     0.142
  Nicorandil, *n* (%)                                        29 (9.6)          71 (10.4)     0.726
  Statins, *n* (%)                                           37 (12.3)        134 (19.6)     0.005

Abbreviations: NTN, normotension; HTN, hypertension.

###### Characteristics of ACh provocation test in general study population

  *Variables*                                     *NTN (*n=*301)*   *HTN (*n=*685)*  P*-value*
  ---------------------------------------------- ----------------- ----------------- -----------
  Reference diameter after NTG infusion (mm)         2.66±0.59         2.58±0.54     0.119
  Reference diameter after ACh infusion (mm)         1.81±0.47         1.84±0.49     0.504
  Diameter narrowing after ACh infusion (%)         39.39±32.75       37.64±34.42    0.729
  Acetylcholine-induced significant CAS, n (%)      118 (39.2)        245 (35.8)     0.303
  ST-segment change, n (%)                           18 (6.0)          43 (6.3)      0.858
  Chest pain, *n* (%)                               137 (45.5)        284 (41.5)     0.236
  Atrioventricular block, *n* (%)                    73 (24.3)        161 (23.5)     0.799
  Myocardial bridge, *n* (%)                         73 (24.3)        163 (23.8)     0.877

Abbreviations: NTG, nitroglycerine; ACh, acetylcholine; CAS, coronary artery spasm.

###### Characteristics of acetylcholine provocation test in patients with significant coronary artery spasm

  *Variables, n* (%)                          *NTN (*n=*118)*   *HTN (*n=*245)*   P*-value*
  ------------------------------------------- ----------------- ----------------- -----------
  *Maximal tolerable dose of acetylcholine*                                       
   A1 (20 μg min^−1^)                         11 (9.3)          18 (7.3)          0.516
   A2 (50 μg min^−1^)                         63 (53.4)         140 (57.1)        0.500
   A3 (100 μg min^−1^)                        44 (37.3)         87 (35.5)         0.741
                                                                                   
  *Spasm types*                                                                   
   Focal                                      14 (11.9)         40 (16.3)         0.263
   Diffuse                                    104 (88.1)        205 (83.7)        0.263
                                                                                   
  *Spasm vessel number*                                                           
   One vessel                                 58 (49.2)         122 (49.8)        0.909
   Multivessel                                60 (50.8)         123 (50.2)        0.909

###### Baseline clinical characteristics of hypertensive patients with vs without controlled blood pressure

  *Variables*                                             *Uncontrolled (*n=*373)*   *Controlled (*n=*312)*   P*-value*
  ------------------------------------------------------ -------------------------- ------------------------ -----------
  Male, n (%)                                                    177 (47.5)                150 (48.1)           0.871
  Age (years)                                                   55.77±11.78               55.64±12.13           0.889
  Body mass index (kg m^−2^)                                     24.35±3.12                24.14±3.24           0.483
  Diabetes mellitus, *n* (%)                                     47 (12.6)                 39 (12.5)            0.968
  Hyperlipidemia, *n* (%)                                        47 (12.6)                 72 (23.1)           \<0.001
  Current smoking, *n* (%)                                       78 (20.9)                 66 (21.2)            0.938
  Family history of coronary artery disease, *n* (%)              22 (5.9)                  20 (6.4)            0.781
  Peripheral arterial disease, *n* (%)                            21 (5.6)                 57 (18.3)           \<0.001
  Systolic blood pressure (mm Hg)                               159.98±15.92              128.52±11.38         \<0.001
  Diastolic blood pressure (mm Hg)                              92.97±10.43                80.89±9.40          \<0.001
  Pulse pressure (mm Hg)                                        67.02±14.39                47.64±9.49          \<0.001
  Total cholesterol (mg per 100 ml)                             178.21±40.72              174.51±37.19          0.246
  Triglyceride (mg per 100 ml)                                  130.37±84.54             139.89±108.50          0.258
  Low-density lipoprotein cholesterol (mg per 100 ml)           111.58±69.40              115.67±32.27          0.613
  High-density lipoprotein cholesterol (mg per 100 ml)          53.12±20.41               51.52±14.43           0.300
  Aspirin, *n* (%)                                               96 (25.7)                 84 (26.9)            0.725
  Cilostazol, *n* (%)                                             7 (1.9)                   6 (1.9)             0.965
  β-Blockers, *n* (%)                                             36 (9.7)                  26 (8.3)            0.549
  Calcium channel blockers, *n* (%)                              158 (42.4)                165 (52.9)           0.006
  Angiotensin-converting enzyme inhibitors, *n* (%)               17 (4.6)                  15 (4.8)            0.877
  Angiotensin II receptor blockers, *n* (%)                      62 (16.2)                 32 (10.3)            0.016
  Nitrates, *n* (%)                                              81 (21.7)                 93 (29.8)            0.015
  Nicorandil, *n* (%)                                            38 (10.2)                 33 (10.6)            0.868
  Statins, *n* (%)                                               71 (19.0)                 63 (20.2)            0.704

###### Characteristics of acetylcholine provocation test in hypertensive patients with vs without controlled blood pressure

  *Variables*                                       *Uncontrolled (*n=*373)*   *Controlled (*n=*312)*   P*-value*
  ------------------------------------------------ -------------------------- ------------------------ -----------
  Reference diameter after NTG infusion (mm)               2.56±0.60                 2.59±0.55            0.256
  Reference diameter after ACh infusion (mm)               1.87±0.41                 1.73±0.43            0.314
  Diameter narrowing after ACh infusion, (%)              33.51±34.87               45.62±35.71           0.243
  Acetylcholine-induced significant CAS, *n* (%)           104 (27.9)                141 (45.2)          \<0.001
  ST-segment change, *n* (%)                                21 (5.6)                  22 (7.1)            0.445
  Chest pain, *n* (%)                                      136 (36.5)                148 (47.4)           0.004
  Atrioventricular block, *n* (%)                          93 (24.9)                 76 (24.4)            0.862
  Myocardial bridge, *n* (%)                               61 (16.4)                 102 (32.7)           0.001

###### Characteristics of acetylcholine provocation test in hypertensive patients with significant coronary artery spasm

  *Variables,* n (%)                          *Uncontrolled (*n=*104)*   *Controlled (*n=*141)*   P-*value*
  ------------------------------------------- -------------------------- ------------------------ -----------
  *Maximal tolerable dose of acetylcholine*                                                       
   A1 (20 μg min^−1^)                         7 (6.7)                    11 (7.8)                 0.751
   A2 (50 μg min^−1^)                         53 (51.0)                  87 (61.7)                0.093
   A3 (100 μg min^−1^)                        44 (42.3)                  43 (30.5)                0.056
                                                                                                   
  *Spasm types*                                                                                   
   Focal                                      19 (18.3)                  21 (14.9)                0.480
   Diffuse                                    85 (81.7)                  120 (85.1)               0.480
                                                                                                   
  *Spasm vessel number*                                                                           
   One vessel                                 52 (50.0)                  70 (49.6)                0.956
   Multivessel                                52 (50.0)                  71 (50.4)                0.956
